LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Aandelen Lijst・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

719.66 -0.26

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

708.04

Max

729.83

Belangrijke statistieken
By Trading Economics
Inkomsten	-117M 727M
Verkoop	-279M 3.6B
K/W Sectorgemiddelde	17.393 51.415
EPS	9.47
Dividendrendement	0.5
Winstmarge	20.17
Werknemers	15,343
EBITDA	-234M 967M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+22.32% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	0.50% 2.34%
Volgende Winsten	31 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-3.3B 75B
Vorige openingsprijs	719.92
Vorige sluitingsprijs	719.66

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

542.44 / 599.76 Steun & Weerstand

Regeneron Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 aug 2025, 11:33 UTC

Winsten

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

29 apr 2026, 12:01 UTC

Winsten

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

23 apr 2026, 21:48 UTC

Acquisities, Fusies, Overnames

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

11 mrt 2026, 11:02 UTC

Marktinformatie

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

14 dec 2025, 08:30 UTC

Acquisities, Fusies, Overnames

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

1 aug 2025, 13:16 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 12:40 UTC

Winsten

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 aug 2025, 10:41 UTC

Winsten

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1 aug 2025, 10:41 UTC

Winsten

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1 aug 2025, 10:40 UTC

Winsten

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1 aug 2025, 10:38 UTC

Winsten

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1 aug 2025, 10:37 UTC

Winsten

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1 aug 2025, 10:35 UTC

Winsten

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1 aug 2025, 10:34 UTC

Winsten

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1 aug 2025, 10:33 UTC

Winsten

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1 aug 2025, 10:32 UTC

Winsten

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1 aug 2025, 10:31 UTC

Winsten

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1 aug 2025, 10:31 UTC

Winsten

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Rev $3.68B >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q EPS $12.81 >REGN

1 aug 2025, 10:30 UTC

Winsten

Regeneron Pharma 2Q Net $1.39B >REGN

13 jun 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 20:45 UTC

Acquisities, Fusies, Overnames

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Acquisities, Fusies, Overnames

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5 jun 2025, 01:41 UTC

Acquisities, Fusies, Overnames

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30 mei 2025, 08:58 UTC

Populaire aandelen

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Peer Vergelijking

Prijswijziging

Regeneron Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

22.32% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 884.89 USD 22.32%

Hoogste 1,057 USD

Laagste 762 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Regeneron Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Gebaseerd op 19 analisten die aandelenratings hebben gegeven aan Regeneron Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

542.44 / 599.76Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.